Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04454229
Other study ID # PALACE1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date December 2, 2022

Study information

Verified date March 2023
Source Austin Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Whilst validated tools exist to enable inpatient penicillin assessment and de-labelling, limited evidence is available regarding the safety and efficacy in the outpatient clinic. The ability to deliver point-of-care penicillin allergy testing for a large cohort of patients, without skin testing, will improve patient access to testing and utilization of preferred penicillin antibiotics.


Description:

Patient-reported penicillin allergies result in poor health outcomes for patients and drive inappropriate antibiotic prescribing, antimicrobial resistance and healthcare costs. Our group has internally and externally validated a novel penicillin allergy clinician decision rule (PEN-FAST) that is able to identify low risk penicillin allergies with a negative predictive value of 96% (95%; 94-98%). Therefore, whilst validated tools exist to enable inpatient penicillin assessment and de-labelling, limited evidence is available regarding the safety and efficacy in the outpatient clinic. The ability to deliver point-of-care penicillin allergy testing for a large cohort of patients, without skin testing, will improve patient access to testing and utilization of preferred penicillin antibiotics.


Recruitment information / eligibility

Status Completed
Enrollment 382
Est. completion date December 2, 2022
Est. primary completion date December 2, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult patients referred to the outpatient allergy clinic for a penicillin allergy history; 2. Willing and able to give consent. Exclusion Criteria: 1. Patient age is < 18 years; 2. Patients with a PEN-FAST score less than 3 3. Pregnancy; 4. Any other illness that, in the investigator's judgement, will substantially increase the risk associated with subject's participation in this study; 5. Patients with history of type A adverse drug reaction, drug-associated anaphylaxis, idiopathic urticaria/anaphylaxis, mastocytosis, serum sickness, blistering skin eruption or acute interstitial nephritis; 6. Patients where the allergy history was not able to be confirmed with patient; 7. Patients on concurrent antihistamine therapy; 8. Patients receiving more than stress dose steroids (i.e. > 50mg QID hydrocortisone [or steroid equivalent]).

Study Design


Intervention

Other:
Direct oral penicillin challenge
The patient will receive a single dose of oral penicillin, following baseline vital signs.
Standard of care
Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.

Locations

Country Name City State
Australia Austin Health Heidelberg Victoria
Australia Peter MacCallum Cancer Center Melbourne Victoria
Australia Royal Melbourne Hospital Melbourne Victoria
Canada McGill University Health Centre (MUHC) Montreal Quebec
United States Duke University Medical Center Durham North Carolina
United States Vanderbilt University Medical Center Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Austin Health

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

References & Publications (3)

Devchand M, Urbancic KF, Khumra S, Douglas AP, Smibert O, Cohen E, Sutherland M, Phillips EJ, Trubiano JA. Pathways to improved antibiotic allergy and antimicrobial stewardship practice: The validation of a beta-lactam antibiotic allergy assessment tool. — View Citation

Trubiano JA, Smibert O, Douglas A, Devchand M, Lambros B, Holmes NE, Chua KY, Phillips EJ, Slavin MA. The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study. Open Forum Infect Dis. 2018 Nov 17;5(12):o — View Citation

Trubiano JA, Vogrin S, Chua KYL, Bourke J, Yun J, Douglas A, Stone CA, Yu R, Groenendijk L, Holmes NE, Phillips EJ. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Intern Med. 2020 May 1;180(5):745-752. doi: 10.1001/jamaint — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The difference in the proportion of positive oral challenges (i.e. immune-mediated reaction) up to 48H after oral challenge
Secondary Proportion of patients referred to the outpatient allergy clinic that are eligible for intervention (i.e randomization) as per protocol [Eligibility to screened ratio] Before randomization
Secondary Feasibility of recruitment defined as the proportion of patients consenting to participate in the study as per protocol from eligible patients. [Recruitment to eligibility ratio]. Before randomization
Secondary Feasibility of intervention delivery defined as the proportion of patients randomized to the intervention arm who had the intervention delivered as per protocol. [Intervention to recruitment ratio] Before randomization
Secondary The proportion of patients with a penicillin allergy who experience an antibiotic associated immune mediated adverse event OR severe adverse drug reaction as per protocol definitions. Up to 48h after the drug challenge
Secondary The proportion of patients with a penicillin allergy who experience an antibiotic associated non-immune mediated adverse event. Up to 48h after the drug challenge
Secondary The proportion of patients that will respect the protocol (protocol compliance) Up to 48h after the drug challenge
Secondary Proportion of patient with positive Penicillin Skin Testing Up to 48h after the drug challenge
Secondary Proportion of patients with non-immune mediated positive oral provocation Up to 48h after the drug challenge
Secondary Proportion of patients with severe adverse reaction - anaphylaxis/death Up to 48h after the drug challenge
Secondary Time from randomization to delabelling Up to 48h after the drug challenge
Secondary Number of appointments required for Penicillin delabelling Up to 48h after the drug challenge
Secondary Assessment with the Pre-Questionnaire and the 6 months follow-up Questionnaire Up to 6 months after the drug challenge
See also
  Status Clinical Trial Phase
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Completed NCT03918772 - Clinical Determinants and Perioperative Allergic Reactions (CADECAP Study)
Completed NCT03688074 - Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) Phase 2
Completed NCT03054428 - Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Phase 3
Recruiting NCT00312312 - Allergy Towards Grass and Bronchial Inflammation - Related to Immunotherapy and Exhaled Nitrogen Oxide N/A
Completed NCT02162576 - Asthma Data Innovation Demonstration Project N/A
Active, not recruiting NCT00887939 - Pathogenesis of Physical Induced Urticarial Syndromes
Completed NCT03627767 - Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects Phase 3
Completed NCT00102570 - Clinical and Immunological Evaluation of Children With Allergies N/A
Completed NCT02163122 - Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC) Early Phase 1
Completed NCT05661812 - Norwegian Birch Rust Allergy Study
Completed NCT02503800 - The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy
Recruiting NCT04322838 - Tromsø Birch Rust Allergy Study. Allergy to Birch Rust, a Possible Explanation to Seasonal Airway Allergy During Autumn?
Completed NCT01257191 - A Study to Compare the Effects of Different Sized Particles on Cells in the Nose Phase 1
Recruiting NCT05420935 - Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating Room N/A